Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies (e.g., corticosteroids) are often effective for mild disease but suffer from suboptimal safety, tolerability, and compliance. More-effective therapies for topical-refractory patients and, more generally, those with moderate to severe AD are also sorely needed and are a key focus of the burgeoning AD pipeline. Pfizer’s nonsteroidal topical Eucrisa (crisaborole) and Sanofi/Regeneron’s injectable biologic Dupixent (dupilumab) are the first in a series of new entrants we expect to transform the AD treatment algorithm. This report provides a comprehensive analysis of AD patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of emerging drugs.
- How large are the mild, moderate, and severe AD subpopulations, and how will they change by 2027? How well are these populations served by current AD therapies?
- How have the launches of Pfizer’s Eucrisa and Sanofi/Regeneron’s Dupixent altered the ADtreatment landscape?
- What emerging therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
- What are the greatest unmet needs, and to what degree will emerging therapies in the pipeline address these needs?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.